论文部分内容阅读
目的:比较普拉克索与左旋多巴用于治疗帕金森病的临床疗效。方法:选取2013年4月—2014年4月收治的帕金森病患者80例,将其分为对照组和观察组,每组40例;对照组患者均给予左旋多巴片治疗,观察组患者给予盐酸普拉克索片治疗,比较两组患者治疗后的UPDRSⅡ、UPDRSⅢ评分值和不良反应的发生率。结果:治疗前两组患者UPDRSⅡ、UPDRSⅢ指标评分值经比较其差异无统计学意义(P>0.05);治疗后观察组患者UPDRSⅡ、UPDRSⅢ指标评分值分别为(7.82±3.54)分和(18.53±8.22)分,明显低于对照组分别为(11.48±3.66)分和(27.93±8.55)分(P<0.05);观察组患者治疗后不良反应的发生率为17.50%高于对照组为7.50%(P>0.05)。结论:普拉克索用于治疗帕金森病患者,其日常活动和运动功能的改善均优于左旋多巴,但普拉克索不良反应的发生率高于对照组。
Objective: To compare the clinical efficacy of pramipexole and levodopa in the treatment of Parkinson’s disease. Methods: Eighty patients with Parkinson’s disease who were admitted from April 2013 to April 2014 were selected and divided into control group and observation group, 40 cases in each group. Patients in the control group were treated with levodopa tablets. Patients in the observation group Given pramipexole hydrochloride tablets treatment, the two groups of patients after treatment UPDRS Ⅱ, UPDRS Ⅲ scores and the incidence of adverse reactions. Results: The scores of UPDRS Ⅱ and UPDRS Ⅲ in the two groups before treatment were not significantly different (P> 0.05). After treatment, the scores of UPDRS Ⅱ and UPDRS Ⅲ in the observation group were (7.82 ± 3.54) and (18.53 ± 8.22), which was significantly lower than that of the control group (11.48 ± 3.66) and (27.93 ± 8.55) points respectively (P <0.05). The incidence of adverse reactions in the observation group after treatment was 17.50% higher than that in the control group (7.50% (P> 0.05). Conclusion: Pramipexole is superior to levodopa in improving daily activities and motor function in Parkinson’s disease patients, but the incidence of pramipexole adverse reactions is higher than that of the control group.